A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Marijuana and its CD4 Receptors: A New HIV Treatment Strategy?
Pathway to a Cure: Cancer Drug Helps Purge HIV From Resting Cells
Life Expectancy With HIV Increases Dramatically
Undetectable Viral Load? Not Necessarily in Semen
Engineering CD8 Cells to Kill HIV in Tissues
Pathway to a Cure: Positive Results Continue for Sangamo's CCR5 Gene Therapy
Revised U.S. Guidelines: HIV Treatment is Recommended for All People Living With HIV
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailprint

September 4, 2007

Metformin Shows Little Lipodystrophy Benefit in Small Study

New research suggests that lipodystrophy sufferers should approach metformin with caution. The study, published in the October HIV Medicine, found little benefit and reasons for concern when using metformin to improve some of the side effects commonly associated with lipodystrophy.

Researchers in Boston enrolled 48 men and women who’d accumulated significant fat at the waistline and had mild insulin resistance. Participants were randomly assigned to take either 1500mg of metformin, an anti-diabetes drug, or a placebo for 24 weeks. The researchers conducted computerized and X-ray scans of body fat and measured insulin sensitivity and cholesterol at baseline and at 24 weeks.

In the study, people taking metformin had no significant changes in visceral fat mass or insulin sensitivity compared to the placebo group. They did, however, lose fat in their arms and legs, leading researchers to recommend that metformin only be used in people who have more severe insulin resistance and no peripheral fat loss.


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    charliehunter
    San Francisco
    California


    Sin_Grinder
    Genoa
    Nevada


    sable22
    Orlando
    Florida


    robert12
    Queens
    New York
Click here to join POZ Personals!
Conference Coverage

19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)
Seattle, Washington
March 5 - 8, 2012


6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011)
Rome, Italy
July 17 - 20, 2011


18th Conference on Retroviruses and Opportunistic Infections (CROI 2011)
Boston, MA
February 27 - March 2, 2011


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.